SpringWorks Therapeutics Profit Margin 2019-2022 | SWTX

Current and historical gross margin, operating margin and net profit margin for SpringWorks Therapeutics (SWTX) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. SpringWorks Therapeutics net profit margin as of March 31, 2022 is 0%.
SpringWorks Therapeutics Annual Profit Margins
SpringWorks Therapeutics Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.614B $0.035B
SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics Inc. is based in Stamford, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.449B 10.01
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.298B 16.25
Biohaven Pharmaceutical Holding (BHVN) United States $10.114B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.068B 0.00
Emergent Biosolutions (EBS) United States $1.695B 7.26
Arcus Biosciences (RCUS) United States $1.307B 33.13
Myovant Sciences (MYOV) United Kingdom $0.933B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.493B 0.00
Gelesis Holdings (GLS) United States $0.348B 0.00
Zymeworks (ZYME) Canada $0.342B 0.00
Ambrx Biopharma (AMAM) United States $0.162B 0.00
Enzo Biochem (ENZ) United States $0.112B 23.00
SQZ Biotechnologies (SQZ) United States $0.094B 0.00